Keros Therapeutics, Inc. (KROS)
11.69
+0.91
(+8.44%)
USD |
NASDAQ |
Aug 25, 16:00
11.69
0.00 (0.00%)
After-Hours: 17:19
Keros Therapeutics Net Income (Quarterly) : -28.71M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -28.71M |
| March 31, 2026 | -23.71M |
| December 31, 2025 | -23.46M |
| September 30, 2025 | -7.28M |
| June 30, 2025 | -30.70M |
| March 31, 2025 | 148.45M |
| December 31, 2024 | -46.03M |
| September 30, 2024 | -52.96M |
| June 30, 2024 | -45.26M |
| March 31, 2024 | -43.11M |
| December 31, 2023 | -40.24M |
| September 30, 2023 | -39.44M |
| June 30, 2023 | -37.50M |
| March 31, 2023 | -35.80M |
| December 31, 2022 | -29.72M |
| Date | Value |
|---|---|
| September 30, 2022 | -23.51M |
| June 30, 2022 | -27.27M |
| March 31, 2022 | -24.19M |
| December 31, 2021 | -6.94M |
| September 30, 2021 | -20.30M |
| June 30, 2021 | -15.62M |
| March 31, 2021 | -15.88M |
| December 31, 2020 | -10.68M |
| September 30, 2020 | -12.04M |
| June 30, 2020 | -10.76M |
| March 31, 2020 | -11.89M |
| December 31, 2019 | -2.751M |
| September 30, 2019 | -3.549M |
| June 30, 2019 | -2.853M |
| March 31, 2019 | -3.183M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Incyte Corp. | 585.60M |
| Nurix Therapeutics, Inc. | -89.54M |
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Anika Therapeutics, Inc. | 3.309M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 28.71M |
| EPS Diluted (Quarterly) | -1.45 |
| Enterprise Value | -28.14M |
| Earnings Yield | -31.65% |
| Normalized Earnings Yield | -31.63 |